Citations

Mayo Clinic

Showing 10 of 108602 citations.

Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence
Kottke, Tim , Evgin, Laura , Shim, Kevin G. , Rommelfanger, Diana M., Boisgerault, Nicolas , Zaidi, Shane, Díaz, Rosa María, Thompson, Jill , Ilett, Elizabeth J. , Selby, Peter J. , Pandha, Hardev , Harrington, Kevin J. , Melcher, Alan , Vile, Richard G. , Rommelfanger, Diana, Ilett, Elizabeth J , Melcher, Alan A , Shim, Kevin G , Harrington, Kevin , Coffey, Matt C.

Cancer Immunology Research | October 17, 2017 | Volume: 5 | Issue: 11 | Pages: 1029-1045

10.1158/2326-6066.cir-17-0175 | PMID 29038298 Get It

AbstractUnderstanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition is mediated through the subversion of two key elements of innate immunosurveillance. In the first, the role of TNFα changes from an antitumor effector against primary tumors into a growth promoter for MRD. Second, whereas primary tumors induced a natural killer (NK)–mediated cytokine response characterized by low IL6 and elevated IFNγ, PD-L1hi MRD cells promoted the secretion of IL6 but minimal IFNγ, inhibiting both NK-cell and T-cell surveillance. Tumor recurrence was promoted by trauma- or infection-like stimuli inducing VEGF and TNFα, which stimulated the growth of MRD tumors. Finally, therapies that blocked PD-1, TNFα, or NK cells delayed or prevented recurrence. These data show how innate immunosurveillance mechanisms, which control infection and growth of primary tumors, are exploited by recurrent, competent tumors and identify therapeutic targets in patients with MRD known to be at high risk of relapse. Cancer Immunol Res; 5(11); 1029–45. ©2017 AACR.
More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma
Jun, Tomi , Yang, Ju Dong , Chen, Vincent , Nguyen, Pauline, Giama, Nasra H., Huang, Chung‐Feng , Hsing, Ann W. , Chuang, Wan‐Long , Roberts, Lewis R. , Yu, Ming‐Lung , Nguyen, Mindie H. , Nguyen, Mindie H , Roberts, Lewis R , Chen, V L , Yu, M-L , Yeh, Ming-Lun , Yang, Ju Dong , Dai, Chia-Yen , Huang, Jee‐Fu

Liver International | October 16, 2017 | Volume: 38 | Issue: 5 | Pages: 895-902

10.1111/liv.13613 | PMID 29045023 Get It

AbstractBackground & AimsAlthough hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major risk factors for hepatocellular carcinoma (HCC), non‐viral causes of HCC, particularly non‐alcoholic fatty liver disease (NAFLD), are becoming increasingly prevalent. The aim of this study was to compare the clinical characteristics and survival of cryptogenic and viral HCC.MethodsWe conducted a retrospective cohort study involving 3878 consecutive HCC patients seen at two tertiary centres in the United States and one in Taiwan from 2004 to 2014. We compared the clinical characteristics, treatment and survival of patients by underlying aetiology: cryptogenic (n = 696), HBV (n = 1304) or HCV (n = 1878).ResultsCirrhosis was present in 66.8% of the cryptogenic HCC patients, compared with 74.7% of HBV‐related HCC (HBV‐HCC) (P = .001) and 85.9% of HCV‐HCC (P < .001). Compared to viral HCC, cryptogenic HCC patients presented with larger tumours and at later stages of disease. Five‐year overall survival was 16.3% among cryptogenic HCC patients compared with 31.9% among HBV‐HCC patients and 27.7% among HCV‐HCC patients (P < .001 for both by the log‐rank test). HCC aetiology was not an independent predictor of survival, though ethnicity, cirrhosis status, meeting Milan criteria and treatment allocation were.ConclusionsCompared with viral HCC patients, those with cryptogenic HCC had lower prevalence of cirrhosis, were diagnosed with larger tumours at more advanced stages of disease, and had poorer overall survival. Additional efforts are needed to identify patients at risk of cryptogenic HCC and to identify cryptogenic HCC at earlier stages of disease.
Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases
Gall, Émilie Cornec-Le , Torres, Vicente E. , Cornec-Le Gall, Emilie, Torres, Vicente E , Harris, Peter C. , Cornec-Le Gall, Emilie

Journal of the American Society of Nephrology | October 16, 2017 | Volume: 29 | Issue: 1 | Pages: 13-23

10.1681/asn.2017050483 | PMID 29038287 Get It

Data indicate significant phenotypic and genotypic overlap, plus a common pathogenesis, between two groups of inherited disorders, autosomal dominant polycystic kidney diseases (ADPKD), a significant cause of ESRD, and autosomal dominant polycystic liver diseases (ADPLD), which result in significant PLD with minimal PKD. Eight genes have been associated with ADPKD ( PKD1 and PKD2 ), ADPLD ( PRKCSH , SEC63 , LRP5 , ALG8 , and SEC61B ), or both ( GANAB ). Although genetics is only infrequently used for diagnosing these diseases and prognosing the associated outcomes, its value is beginning to be appreciated, and the genomics revolution promises more reliable and less expensive molecular diagnostic tools for these diseases. We therefore propose categorization of patients with a phenotypic and genotypic descriptor that will clarify etiology, provide prognostic information, and better describe atypical cases. In genetically defined cases, the designation would include the disease and gene names, with allelic (truncating/nontruncating) information included for PKD1 . Recent data have shown that biallelic disease including at least one weak ADPKD allele is a significant cause of symptomatic, very early onset ADPKD. Including a genic (and allelic) descriptor with the disease name will provide outcome clues, guide treatment, and aid prevalence estimates.
Effect of nephrectomy for retroperitoneal sarcoma on post‐operative renal function
Kim, Daniel B. , Gray, Richard J. , Li, Zhuo , Wasif, Nabil , Kim, Daniel B. , Bagaria, Sanjay P.

Journal of Surgical Oncology | October 16, 2017 | Volume: 117 | Issue: 3 | Pages: 425-429

10.1002/jso.24875 | PMID 29044533 Get It

Background and ObjectivesSurgical resection of retroperitoneal sarcomas (RPS) often involves removal of the ipsilateral kidney. We evaluated the long‐term post‐operative renal function in patients who underwent a nephrectomy as part of their en‐bloc resection of RPS.MethodsRetrospective review of an institutional database identified RPS patients who underwent nephrectomy for curative intent from 1990 to 2014. The primary outcome measured was chronic kidney disease (CKD) calculated by the glomerular filtration rate (GFR).ResultsOf the 47 patients in our study, 19 (40%), 18 (38%), and 10 (21%) patients had a preoperative CKD stage 1, 2, and 3, respectively. The GFR decreased by an average of 33.4 mL/min/1.73 m2 with 66% of patients demonstrating mild progression of their renal impairment. Only three (6%) patients progressed to CKD stage 4 or 5, one of which required life‐long dialysis.ConclusionNephrectomy as part of an en‐bloc resection is associated with a decrease in GFR that is not clinically significant. Fear of kidney failure should not prevent a surgeon from performing a nephrectomy in the treatment of RPS.
Provider views on the management of Ewing sarcoma of the spine and pelvis
Zhu, Chong , Olson, Kristofor A. , Geller, David S. , Görlick, Richard , Laack, Nadia N. , Randall, RL, Laack, Nadia N Issa , Gorlick, Richard , Roth, Michael , Gill, Jonathan Benjamin

Journal of Surgical Oncology | October 16, 2017 | Volume: 117 | Issue: 3 | Pages: 417-424

10.1002/jso.24860 | PMID 29044582 Get It

BackgroundCurative therapy for ES requires both chemotherapy and local control of primary tumor. There is no universally accepted standard approach to local control modalities. This survey was conducted to determine practice patterns and factors influencing the choice to offer various local control modalities to patients with ES of the spine and pelvis.MethodsThe survey consisted of four scenarios involving a 15‐year‐old girl who presented with Ewing sarcoma of thoracic vertebra, sacrum, iliac wing, and acetabulum with or without neurologic compromise. The questionnaire was sent to oncologists, orthopedic surgeons, and radiation oncologists, asking their recommendations for local control modality.ResultsAmong 94 respondents, radiotherapy was most frequently chosen for sacral tumors (68.1%) and T10 vertebral tumors (46.2%) whereas surgery was preferred for iliac wing pelvic tumors (45.7%) and acetabular tumors (43.6%). Orthopedic surgeons were significantly more likely to offer surgery than radiation oncologists (OR 3.07, 95%CI 1.37‐6.88, P = 0.007). Providers outside North America were more likely to offer combined surgery plus radiotherapy (OR 10.58, 95%CI 5.41‐20.70, P < 0.001).ConclusionConsiderable heterogeneity exists in local control modalities for Ewing sarcoma of the spine and pelvis. Specialty and location of practice may influence treatment recommendations.
TIEG and estrogen modulate SOST expression in the murine skeleton
Subramaniam, Malayannan , Pitel, Kevin S., Bruinsma, Elizabeth S. , Hawse, John R. , Monroe, David G. , Hawse, John R

Journal of Cellular Physiology | October 16, 2017 | Volume: 233 | Issue: 4 | Pages: 3540-3551

10.1002/jcp.26211 | PMID 29044507 Get It

TIEG knockout (KO) mice exhibit a female‐specific osteopenic phenotype and altered expression of TIEG in humans is associated with osteoporosis. Gene expression profiling studies identified sclerostin as one of the most highly up‐regulated transcripts in the long bones of TIEG KO mice relative to WT littermates suggesting that TIEG may regulate SOST expression. TIEG was shown to substantially suppress SOST promoter activity and the regulatory elements through which TIEG functions were identified using promoter deletion and chromatin immunoprecipitation assays. Knockdown of TIEG in IDG‐SW3 osteocyte cells using shRNA and CRISPR‐Cas9 technology resulted in increased SOST expression and delayed mineralization, mimicking the results obtained from TIEG KO mouse bones. Given that TIEG is an estrogen regulated gene, and as changes in the hormonal milieu affect SOST expression, we performed ovariectomy (OVX) and estrogen replacement therapy (ERT) studies in WT and TIEG KO mice followed by miRNA and mRNA sequencing of cortical and trabecular compartments of femurs. SOST expression levels were considerably higher in cortical bone compared to trabecular bone. In cortical bone, SOST expression was increased following OVX only in WT mice and was suppressed following ERT in both genotypes. In contrast, SOST expression in trabecular bone was decreased following OVX and significantly increased following ERT. Interestingly, a number of miRNAs that are predicted to target sclerostin exhibited inverse expression levels in response to OVX and ERT. These data implicate important roles for TIEG and estrogen‐regulated miRNAs in modulating SOST expression in bone.
Clinical Reasoning: A 46-year-old man with persistent hiccups, cognitive dysfunction, and imbalance
Lamb, Christopher J. , López‐Chiriboga, A. Sebastian , Mendez, Julio, Robinson, Maisha T. , Sotello Aviles, David A , Mendez, Julio C, Lamb, Christopher J , Sotello, David

Neurology | October 16, 2017 | Volume: 89 | Issue: 16 | Pages: No page available

10.1212/wnl.0000000000004523 | PMID 29038139 Get It

Teaching Neuro Images : Spontaneous involution of symptomatic delayed tumefactive cyst following radiosurgery for AVM
Aiello, Giovanni, Snyder, Kendall, Brinjikji, Waleed , Lanzino, Giuseppe

Neurology | October 16, 2017 | Volume: 89 | Issue: 16 | Pages: No page available

10.1212/wnl.0000000000004520 | PMID 29038141 Get It

Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer
García, S. Gómez , Schuh, Michael J. , Cheema, Anvir, Atwal, Herjot, Atwal, Paldeep S. , Schuh, Michael, Atwal, Paldeep S

Case Reports in Genetics | October 16, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-4

10.1155/2017/6236714 | PMID 29123929 Get It

Cardiotoxicity has been extensively reported in venlafaxine (VEN) overdoses. Asthenia is also among the common side effects described for this antidepressant. VEN is metabolized mainly by CYP2D6 and to a minor extent by CYP2C19 to the major active metabolite O-desmethylvenlafaxine (ODV). Altered pharmacokinetic parameters in patients with polymorphisms in the CYP2D6 and CYP2C19 genes that result in decreased enzymatic activity have been documented. Here we describe a patient case of VEN associated palpitations and asthenia. The patient takes VEN extended release 150 mg twice daily. Genotyping confirmed the patient is a poor metabolizer for CYP2D6 and an intermediate metabolizer for CYP2C19. We propose that the palpitations and asthenia are related to sustained VEN exposure due to reduced metabolism.
Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis
Okamoto, Kohji , Takada, Tadahiro , Strasberg, Steven M. , Asbun, Horacio J. , Endo, Itaru , Iwashita, Yukio , Hibi, Taizo , Pitt, Henry A. , Umezawa, Akiko , Asai, Koji , Hwang, Tsann‐Long , Mori, Yasuhisa , Huang, Wayne Shih‐Wei, Belli, Giulio, Dervenis, Christos, Yokoe, Masamichi, Kiriyama, Seiki , Itoi, Takao , Jagannath, P., Garden, O. James , Miura, Fumihiko, Wakabayashi, Go , Cherqui, Daniel , Santibáñes, Eduardo de , Shikata, Satoru , Noguchi, Yoshinori , Higuchi, Ryota , Wada, Keita, Supe, Avinash , Yoshida, Masahiro , Mayumi, Toshihiko , Gouma, Dirk J., Deziel, Daniel J., Liau, Kui‐Hin, Chen, Miin‐Fu , Shibao, Kazunori , Liu, Keng‐Hao, Su, Cheng‐Hsi, Chan, Angus C. W., Choi, In‐Seok , Jonas, Eduard , Fan, Sheung Tat , Ker, Chen‐Guo , Giménez, Mariano , Kitano, Seigo, Inomata, Masafumi , Inui, Kazuo, Sumiyama, Yoshinobu, Yamamoto, Masakazu , Suzuki, Kenji S. , Han, Ho-Seong , Yoon, Yoo-Seok , Nakamura, Masafumi , Horiguchi, Akihiko , Ukai, Tomohiko , Honda, Goro , Yoon, Dong Sup , Chen, Xiaoping , Hirata, Koichi , Jonas, Eduard

Journal of Hepato-Biliary-Pancreatic Sciences | October 16, 2017 | Volume: 25 | Issue: 1 | Pages: 55-72

10.1002/jhbp.516 | PMID 29045062 Get It

Abstract We propose a new flowchart for the treatment of acute cholecystitis ( AC ) in the Tokyo Guidelines 2018 (TG18). Grade III AC was not indicated for straightforward laparoscopic cholecystectomy (Lap‐C). Following analysis of subsequent clinical investigations and drawing on Big Data in particular, TG 18 proposes that some Grade III AC can be treated by Lap‐C when performed at advanced centers with specialized surgeons experienced in this procedure and for patients that satisfy certain strict criteria. For Grade I, TG 18 recommends early Lap‐C if the patients meet the criteria of Charlson comorbidity index ( CCI ) ≤5 and American Society of Anesthesiologists physical status classification ( ASA ‐ PS ) ≤2. For Grade II AC , if patients meet the criteria of CCI ≤5 and ASA ‐ PS ≤2, TG 18 recommends early Lap‐C performed by experienced surgeons; and if not, after medical treatment and/or gallbladder drainage, Lap‐C would be indicated. TG 18 proposes that Lap‐C is indicated in Grade III patients with strict criteria. These are that the patients have favorable organ system failure, and negative predictive factors, who meet the criteria of CCI ≤3 and ASA ‐ PS ≤2 and who are being treated at an advanced center (where experienced surgeons practice). If the patient is not considered suitable for early surgery, TG 18 recommends early/urgent biliary drainage followed by delayed Lap‐C once the patient's overall condition has improved. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.